3D Medicines' (HKG:1244) loss attributable to owners in 2024 narrowed year on year to 182.7 million yuan or 0.75 yuan per share, according to a Hong Kong Stock Exchange disclosure on Monday.
The attributable loss a year ago was 524.7 million yuan or 2.30 yuan per share.
The biopharmaceutical company's revenue dropped 30% to 445.6 million yuan from 634.9 million yuan in the previous year, the disclosure said.
No final dividend was recommended for the period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。